AU2005231358A1 - Use of PPR delta agonists for treating demyelinating diseases - Google Patents

Use of PPR delta agonists for treating demyelinating diseases Download PDF

Info

Publication number
AU2005231358A1
AU2005231358A1 AU2005231358A AU2005231358A AU2005231358A1 AU 2005231358 A1 AU2005231358 A1 AU 2005231358A1 AU 2005231358 A AU2005231358 A AU 2005231358A AU 2005231358 A AU2005231358 A AU 2005231358A AU 2005231358 A1 AU2005231358 A1 AU 2005231358A1
Authority
AU
Australia
Prior art keywords
cells
compound
ppar
invitrogen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005231358A
Other languages
English (en)
Inventor
Karen Chandross
Olga Khorkova
Lan Lee
Yun Liu
Jean Merrill
Anne Minnich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU2005231358A1 publication Critical patent/AU2005231358A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005231358A 2004-04-01 2005-03-29 Use of PPR delta agonists for treating demyelinating diseases Abandoned AU2005231358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
US60/558,533 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
AU2005231358A1 true AU2005231358A1 (en) 2005-10-20

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005231358A Abandoned AU2005231358A1 (en) 2004-04-01 2005-03-29 Use of PPR delta agonists for treating demyelinating diseases

Country Status (16)

Country Link
US (1) US20070149580A1 (https=)
EP (1) EP1737440A2 (https=)
JP (1) JP2007530703A (https=)
KR (1) KR20060134191A (https=)
CN (1) CN1950077A (https=)
AU (1) AU2005231358A1 (https=)
BR (1) BRPI0509540A (https=)
CA (1) CA2561159A1 (https=)
IL (1) IL178165A0 (https=)
MA (1) MA28561B1 (https=)
MX (1) MXPA06011218A (https=)
NO (1) NO20064985L (https=)
RU (1) RU2006138495A (https=)
SG (1) SG138623A1 (https=)
WO (1) WO2005097098A2 (https=)
ZA (1) ZA200607850B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
JP5186217B2 (ja) * 2005-11-28 2013-04-17 千寿製薬株式会社 Ｐｐａｒアゴニスト含有医薬
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
MX2010013264A (es) 2008-06-09 2011-02-25 Sanofi Aventis Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas.
WO2010000353A1 (en) 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
JP6068981B2 (ja) 2009-12-17 2017-01-25 サノフイ ミエリン塩基性タンパク質プロモーターの制御下でルシフェラーゼを発現する動物モデル（ｍｂｐ−ｌｕｃｉ）、及び生物発光インビボ画像化のためのモデルの使用
EP3502236B1 (en) * 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist

Also Published As

Publication number Publication date
JP2007530703A (ja) 2007-11-01
BRPI0509540A (pt) 2007-09-18
US20070149580A1 (en) 2007-06-28
ZA200607850B (en) 2008-10-29
CA2561159A1 (en) 2005-10-20
MXPA06011218A (es) 2007-01-16
EP1737440A2 (en) 2007-01-03
IL178165A0 (en) 2008-03-20
WO2005097098A3 (en) 2005-12-22
CN1950077A (zh) 2007-04-18
NO20064985L (no) 2006-10-31
SG138623A1 (en) 2008-01-28
KR20060134191A (ko) 2006-12-27
MA28561B1 (fr) 2007-04-03
WO2005097098A2 (en) 2005-10-20
RU2006138495A (ru) 2008-05-10

Similar Documents

Publication Publication Date Title
US20070149580A1 (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
Granneman et al. Member of the peroxisome proliferator–activated receptor family of transcription factors is differentially expressed by oligodendrocytes
Whitney et al. Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons
US6949380B1 (en) Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
US20190099452A1 (en) Methods for promoting oligodendrocyte regeneration and remyelination
WO2015131788A1 (en) Treatment of neurological conditions
Jana et al. Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes
JP2010528016A (ja) 細胞を刺激するための方法および組成物
US20030082802A1 (en) Method for neural stem cell differentiation using 5ht1a agonists
US9028810B2 (en) Composition for inducing migration of neural stem cells containing periostin as effective ingredient
Zhang et al. Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system
Kaplan et al. Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures?
US11779565B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
Yao et al. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes
AU2005230838A1 (en) 1,3,4-oxadiazol-2-ones as PPAR delta
CN113433324A (zh) Nck1蛋白作为标志物在诊断脊髓损伤中的应用
AU2018420438A1 (en) Treatment for demyelinating disease
US20090155223A1 (en) Cell-based compositions and methods for treating conditions of the nervous system
EP2741759A2 (en) Oligodendrocyte differentiation
WO2017081033A1 (en) Cell differentiation or reprogramming using fezf2 and lmo4
EP3640339A1 (en) Novel screening method for tgf- inhibitor
HK1102384A (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
Meng et al. PPAR-γ Agonist Promotes Proliferation of Neural Stem Cells Via Mitophagy Inhibition
WO2023079079A1 (en) Methods for treating multiple sclerosis
Chojnacki Cellular and molecular properties of mammalian ventral forebrain precursors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application